Morgan Keegan Maintains Market Perform Rating and $38 PT on Medtronic
A report from Morgan Keegan reiterates its Market Perform rating and $38 price target on Medtronic (NYSE: MDT).
The report states, “Medtronic's Ablation Frontiers system for ablating persistent and long-standing persistent atrial fibrillation (AF) will likely not be recommended for approval by the FDA Advisory Panel. We believe the chance could be as low as 30% that Medtronic… will be successful."
MDT closed yesterday at $33.73.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.